A Phase II/III Randomized Double-Blind Multicenter Study Comparing UC-MSC-Derived Secretome and Sodium Hyaluronate in Patients With Knee Osteoarthritis

NCT ID: NCT07337863

Last Updated: 2026-01-13

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-01
• Study Completion Date: 2027-06-17

Brief Summary

This study is a randomized, double-blind, multicenter Phase II/III clinical trial designed to evaluate the effectiveness and safety of umbilical cord-derived mesenchymal stem cell (UC-MSC) secretome compared with sodium hyaluronate in patients with knee osteoarthritis. Knee osteoarthritis is a common degenerative joint disease that causes chronic pain and functional limitation. Participants will be randomly assigned to receive intra-articular injections of either UC-MSC-derived secretome or sodium hyaluronate. The study aims to assess improvements in knee pain, physical function, and overall clinical outcomes, as well as to evaluate the safety of the interventions over the study period.

Detailed Description

This multicenter, randomized, double-blind Phase II/III clinical study aims to compare the efficacy and safety of intra-articular UC-MSC-derived secretome with sodium hyaluronate in patients with Kellgren-Lawrence grade 2-3 knee osteoarthritis. Eligible participants will be randomly allocated to one of two treatment arms. Clinical outcomes will be evaluated using validated pain and functional assessment tools at predefined time points. Safety assessments will include monitoring of adverse events throughout the study period. The results of this study are expected to provide evidence regarding the potential role of UC-MSC-derived secretome as an alternative therapeutic option for knee osteoarthritis.

Conditions

Knee Osteoarthritis (Knee OA)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

UC-MSC-Derived Secretome

Participants receive intra-articular injection of UC-MSC-derived secretome

Group Type: EXPERIMENTAL

Sodium Hyaluronate (Hyalein)

Intervention Type: DRUG

Sodium hyaluronate administered via intra-articular injection as an active comparator.

Sodium Hyaluronate

Participants receive intra-articular injection of sodium hyaluronate

Group Type: ACTIVE_COMPARATOR

UC-MSC-Derived Secretome

Intervention Type: BIOLOGICAL

Umbilical cord-derived mesenchymal stem cell secretome administered via intra-articular injection according to the study protocol.

Interventions

UC-MSC-Derived Secretome

Umbilical cord-derived mesenchymal stem cell secretome administered via intra-articular injection according to the study protocol.

Intervention Type: BIOLOGICAL

Sodium Hyaluronate (Hyalein)

Sodium hyaluronate administered via intra-articular injection as an active comparator.

Intervention Type: DRUG

Other Intervention Names

Sodium Hyaluronate

Eligibility Criteria

Inclusion Criteria

2. Males or females in the age range 40-70 years

3. Symptomatic knee OA (defined by pain at the affected joint for at least 3 months before inclusion and visual analog scale 40 - 70 mm on a 100 mm Visual Analog Scale (VAS).

4. Radiographic evidence of grade 2 to 3 osteoarthritis (OA) based on Kellgren and Lawrence radiographic criteria.

5. Body mass index between 18 - 30 kg/m2

6. Female participants of childbearing age who agreed to use accepted methods of contraception during the course of the study.

7. Ability to provide written informed consent and willing to participate the study

Exclusion Criteria

1. Participants who, based on physical examination and clinical history (anamnesis), are in the active or acute phase of cardiac, pulmonary, hematological, hepatic, renal, systemic autoimmune, immunodeficiency, or coagulation disorders that may interfere with the administration of the study drug (Secretome or Sodium Hyaluronate) will be excluded,

2. Diagnosed with a meniscal rupture based on clinical history (anamnesis) and physical examination. If the anamnesis and physical examination show symptoms and signs of a meniscal rupture, further evaluation will be performed using ultrasound (USG),

3. Participants with significant axial deviation, defined by valgus or varus deformity observed during physical examination, will be excluded,

4. Participants with other pathological lesions on knee X-rays from the screening examination will also be excluded,

5. History of any form of secondary arthritis in the knee due to trauma,

6. History of surgery or major trauma to the knee joint

7. Has knee effusion,

8. Has any other inflammatory disorder of the knee joint

9. Diagnosed with active malignancy.

10. History of stem cell or secretome therapy.

11. Intra-articular injection of corticosteroid and/or prior treatment with Sodium Hyaluronate and/or platelet rich plasma (PRP) in past 3 months.

12. Use of NSAIDs and/or chondroprotective supplements, such as glucosamine and chondroitin sulfate, within 7 days before the trial, whether used orally, topically, or via injection,

13. Undergoing immunosuppressive therapy, or anticoagulant therapy, or corticosteroid therapy.

14. For women of child-bearing potential: positive pregnancy test or lactating (females who were planning pregnancy within the next year were excluded).

15. Enrolled in any other clinical trials within the past four weeks.

16. The principal investigator considers that the participant is ineligible for the clinical trial due to any reasons other than those listed above

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

PT Bifarma Adiluhung

INDUSTRY

Sponsor Role: collaborator

Universitas Sriwijaya

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Radiyati Umi Partan, MD, PhD

Role: STUDY_CHAIR

Universitas Sriwijaya

Locations

RSUP Dr. Mohammad Hoesin Palembang

Palembang, South Sumatera, Indonesia

Countries

Indonesia

Central Contacts

Rudi Erwin Kurniawan, MD, MH

Role: CONTACT

dr.rudierwin@gmail.com

+6282166114111

Facility Contacts

Radiyati Umi Partan, MD, PhD

Role: primary

radiyati.u.p@fk.unsri.ac.id

+62812-7811-6601

Other Identifiers

PML-BFA-04-2024

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

UCMSC-OA-Phase II/III

Identifier Type: -

Identifier Source: org_study_id